Peer-influenced content. Sources you trust. No registration required. This is HCN.

OBR OncologyIbrutinib Outperforms ASCT in Treatment-Naive MCL

Patients with previously untreated mantle cell lymphoma (MCL) have relied on autologous stem cell transplant (ASCT) for more than 20 years; the current standard of care entails high-dose cytarabine-containing chemoimmunotherapy, ASCT, and rituximab maintenance. A recent clinical trial’s findings, which revealed that FFS was superior to ASCT when ibrutinib medication was added, may change this.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form